Table 1.
Patient characteristics
| Characteristics | All patients (N=153) |
|---|---|
| Age at diagnosis, median (range) | 71 years (65–89) |
| Gender, n (%) | |
| Male | 86 (56%) |
| Female | 68 (44.%) |
| Race, n (%) | |
| White | 127 (83%) |
| Black | 16 (10.5%) |
| Asian | 6 (3.9%) |
| Others | 4 (2.6%) |
| ECOG Performance status, n (%) | |
| 0 | 73 (47.7%) |
| 1 | 61 (39.9%) |
| 2 | 15 (9.8%) |
| 3 | 4 (2.6%) |
| Primary site, n (%) | |
| Colon | 130 (85%) |
| Rectum | 23 (15%) |
| Site of metastasis, n (%) | |
| Liver only | 75 (49%) |
| Lung only | 12 (7.9%) |
| Others | 66 (43.1%) |
|
Previous treatment for limited disease, n (%) -None (no limited disease) -Surgery -CCRT -Adjuvant chemotherapy |
62(40.5%) 91 (59.5%) 6 (3.9%) 4 (2.6%) |
|
Chemotherapy received* −5-FU/capecitabine based -Irinotecan-containing -Oxaliplatin-containing -Other |
33 (22%) 31 (20%) 78 (51%) 11 (7%) |
|
Median MAX 2 score, (range) Median number of chemotherapy cycle, (range) |
0.134 (0.025–0.231) 6 (1–17) |
*
First line chemotherapy for metastatic disease. May or may not include monoclonal antibodies as part of the regimen.